Sign inJoin waitlistJoin the waitlist

Nibal Zaghloul

Physician · Saint Peter's University Hospital

Credentials: · · ·

History

Saint Peter's University Hospital
2021–Present

Morgan Stanley Children's Hospital of New York Presbyterian
2006–2009
Pediatric Hematology/Oncology
Westchester Medical Center
2003–2006
Saint Joseph’s Children Hospital in Paterson
2000–2003
American University of Beirut, Lebanon
1997–2000
American University of Beirut School of Medicine Beirut, Lebanon
1993–1997
American University of Beirut, Lebanon

Research

Angiopoietin-1/Tie-2 activation contributes to vascular survival and tumor growth during VEGF blockade
International Journal of Oncology · 2009 · 63 citations
A global initiative to deliver precision health in diabetes
Nature Medicine · 2024 · 22 citations
Vascular endothelial growth factor blockade rapidly elicits alternative proangiogenic pathways in neuroblastoma
International Journal of Oncology · 2009 · First of 9 authors · 21 citations

Angela Kadenhe-Chiweshe
2 papers
Darrell Yamashiro
2 papers
Ionela Iacobas
2 papers
Jae-O Bae
2 papers · 2 as a fellow
Jessica Kandel
2 papers
Adrienne Hammill
1 paper
Amy Geddis
1 paper
AS
Anna Sechser-Perl
1 paper
Beth Drolet
1 paper
Deborah Schiff
1 paper
Denise Adams
1 paper
Elissa Engel
1 paper · 1 as a fellow

Clinical trials

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2031
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
Site PI · Recruiting · Phase 2
Children's Oncology Group
2024–2033
A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study
Site PI · Recruiting · Phase 2
Children's Oncology Group
2024–2027
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2029